Charles River Laboratories International Inc experienced a volatile year in 2024-2025, with its stock price fluctuating significantly, but the company’s strong market position and commitment to innovation provide a foundation for potential recovery …

Charles River Laboratories International Inc. stock surged 18% on July 22, 2025, as the company capitalized on positive sentiment in the healthcare sector despite a challenging year.

Charles River Laboratories International Inc faces challenges in maintaining its competitive edge and financial stability in the life sciences industry, requiring strategic innovation and adaptation to secure its future prospects.

Charles River Laboratories International Inc. reported Q1 2025 earnings of $25.47 million, beating expectations despite a 62% year-over-year decline in profit.

Charles River Laboratories International Inc. reported Q1 earnings that beat expectations, sparking a positive market reaction and a significant increase in its stock price, amidst broader market optimism.

Charles River Laboratories’ stock surged 22% on May 7, 2025, driven by strong earnings and a strategic review of its business operations, marking its best day in 13 years.

Charles River Laboratories International Inc. saw its stock surge 21% after beating Q1 earnings expectations, driven by a strong report and strategic initiatives that boosted investor confidence.

Charles River Laboratories International Inc. sees its stock surge 21% after beating earnings estimates and announcing strategic developments, including a settlement with activist investor Elliott.

Charles River Laboratories is set to release its Q1 earnings report, amidst mixed analyst projections, following a settlement with activist investor Elliott Management and a recent decrease in profits.